H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Precision BioSciences Inc (DTIL) today and set a price target of $21.00. The company’s shares closed last Monday at $6.43, close to its 52-week low of $6.37.
According to TipRanks.com, Chattopadhyay has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.4% and a 32.6% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Precision BioSciences Inc with a $21.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.00 and a one-year low of $6.37. Currently, Precision BioSciences Inc has an average volume of 153.3K.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DTIL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases.
